Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


HIV-1 Infection-Pipeline Review, H1 2015

HIV-1 Infection-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

HIV-1 Infection-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'HIV-1 Infection-Pipeline Review, H1 2015', provides an overview of the HIV-1 Infection's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for HIV-1 Infection, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for HIV-1 Infection and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of HIV-1 Infection

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for HIV-1 Infection and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the HIV-1 Infection products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the HIV-1 Infection pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for HIV-1 Infection

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding HIV-1 Infection pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 8

List of Figures 10

Introduction 11

Global Markets Direct Report Coverage 11

HIV-1 Infection Overview 12

Therapeutics Development 13

Pipeline Products for HIV-1 Infection-Overview 13

Pipeline Products for HIV-1 Infection-Comparative Analysis 14

HIV-1 Infection-Therapeutics under Development by Companies 15

HIV-1 Infection-Therapeutics under Investigation by Universities/Institutes 19

HIV-1 Infection-Pipeline Products Glance 24

Late Stage Products 24

Clinical Stage Products 25

Early Stage Products 26

Unknown Stage Products 27

HIV-1 Infection-Products under Development by Companies 28

HIV-1 Infection-Products under Investigation by Universities/Institutes 33

HIV-1 Infection-Companies Involved in Therapeutics Development 38

AlphaVax, Inc. 38

AltraVax Inc. 39

Aphios Corporation 40

Argos Therapeutics, Inc. 41

Bionor Pharma ASA 42

Biosantech SA 43

Boehringer Ingelheim GmbH 44

Bristol-Myers Squibb Company 45

CompleGen, Inc. 46

Critical Outcome Technologies Inc. 47

CytoDyn Inc. 48

Enzo Biochem, Inc. 49

FIT Biotech Oy 50

GeneCure LLC 51

Gilead Sciences, Inc. 52

GlaxoSmithKline plc 53

Heat Biologics, Inc. 54

InnaVirVax SA 55

Inovio Pharmaceuticals, Inc. 56

Johnson & Johnson 57

Merck & Co., Inc. 58

Mymetics Corporation 59

Myrexis, Inc. 60

Oncovir, Inc. 61

OyaGen Inc. 62

Peregrine Pharmaceuticals, Inc. 63

Pfizer Inc. 64

Pharis Biotec GmbH 65

Spider Biotech 66

TaiMed Biologics Inc. 67

Takara Bio Inc. 68

Theravectys S.A. 69

Tobira Therapeutics, Inc. 70

United Biomedical, Inc. 71

Valens Therapeutics, Inc. 72

Vichem Chemie Research Ltd. 73

ViiV Healthcare Limited 74

HIV-1 Infection-Therapeutics Assessment 75

Assessment by Monotherapy Products 75

Assessment by Combination Products 76

Assessment by Target 77

Assessment by Mechanism of Action 80

Assessment by Route of Administration 83

Assessment by Molecule Type 85

Drug Profiles 87

(cenicriviroc mesylate + lamivudine + efavirenz)-Drug Profile 87

(cenicriviroc mesylate + lamivudine)-Drug Profile 88

(darunavir + cobicistat + emtricitabine + tenofovir alafenamide)-Drug Profile 89

(dolutegravir + rilpivirine)-Drug Profile 91

(elvitegravir + cobicistat + emtricitabine + tenofovir alafenamide)-Drug Profile 92

(emtricitabine + rilpivirine hydrochloride + tenofovir alafenamide)-Drug Profile 94

(emtricitabine + tenofovir alafenamide)-Drug Profile 95

(lamivudine + raltegravir potassium)-Drug Profile 96

1-E703-Drug Profile 97

3B3-PE38-Drug Profile 98

AGS-004-Drug Profile 99

AH-0109-Drug Profile 101

ALVAC-HIV vCP1521 + AIDSVAX B/B-Drug Profile 102

Antibodies to Inhibit gp120 for HIV-1 Infection-Drug Profile 104

Antisense Oligonucleotides to Inhibit GAG for HIV-1 Infection-Drug Profile 105

APH-0812-Drug Profile 106

AVX-101-Drug Profile 107

BMS-585248-Drug Profile 108

BMS-955176-Drug Profile 109

CCL-14-Drug Profile 110

Cell Therapy for HIV-1 Infection-Drug Profile 111

censavudine-Drug Profile 112

CG-1-Drug Profile 114

CGX-0471-Drug Profile 115

CGX-1079-Drug Profile 116

CPI-43132-Drug Profile 117

Dendritic Cell Therapy for HIV-1 Infection-Drug Profile 118

doravirine-Drug Profile 119

Drug to Inhibit Reverse Transcriptase for HIV-1-Drug Profile 120

Drugs to Antagonize P2X for HIV-1 Infection-Drug Profile 121

Drugs to Inhibit HIV-1 Protease for HIV-1 Infection-Drug Profile 122

Drugs to Inhibit Reverse Transcriptase for Viral Infections-Drug Profile 123

Drugs to Inhibit Vif Protein for HIV-1 Infection-Drug Profile 124

DS-001-Drug Profile 125

DS-003-Drug Profile 126

DS-007-Drug Profile 127

F2-Drug Profile 128

FIT-06 + LIPO-5-Drug Profile 129

fostemsavir-Drug Profile 130

FP-1-Drug Profile 132

Gene Therapy for HIV-1 Infection-Drug Profile 133

Gene Therapy to Activate MazF Gene for HIV-1-Drug Profile 134

Gene Therapy to Inhibit Gag for HIV-1 Infection-Drug Profile 136

GRL-0519-Drug Profile 137

GS-8374-Drug Profile 138

GS-9883-Drug Profile 139

GSK-732462-Drug Profile 140

HGTV-43-Drug Profile 141

HIV [serotype 5] vaccine-Drug Profile 142

HIV [type 1] vaccine-Drug Profile 144

HIV Vaccine-Drug Profile 146

HIV vaccine-Drug Profile 147

HIV vaccine-Drug Profile 148

HIV-1 vaccine-Drug Profile 149

HIV-1 vaccine-Drug Profile 150

HIV-1 vaccine-Drug Profile 151

HIV-1 vaccine-Drug Profile 152

HIV-1 vaccine-Drug Profile 153

HIV-1 vaccine-Drug Profile 154

HIV-1 vaccine-Drug Profile 155

HIV-1 vaccine-Drug Profile 156

HIV-1 vaccine-Drug Profile 157

HIV-1 vaccine-Drug Profile 158

HIV-1 vaccine (bivalent)-Drug Profile 159

HIV-1 vaccine 1-Drug Profile 160

HIV-1 vaccine 1-Drug Profile 161

HIV-1 vaccine 3-Drug Profile 162

HIV-1 vaccine 4-Drug Profile 164

HIV-1 vaccine 5-Drug Profile 165

HIVAX-Drug Profile 167

HNG-156-Drug Profile 168

HS-HIV1-Drug Profile 169

HUM-8P.342-Drug Profile 170

ibalizumab-Drug Profile 171

Leukothera-Drug Profile 173

M-48U1-Drug Profile 174

MK-8507-Drug Profile 175

MK-8591-Drug Profile 176

MK-8970-Drug Profile 177

MYMV-101-Drug Profile 178

MYMV-201-Drug Profile 180

NB-325-Drug Profile 181

PENNVAX-B-Drug Profile 183

Peptides to Target TAR for HIV-1 Infection-Drug Profile 185

PF-46396-Drug Profile 186

PGN-632-Drug Profile 187

Poly-ICLC-Drug Profile 188

PRO-140-Drug Profile 190

Protein for HIV-1 Infection-Drug Profile 192

Protein to Inhibit Tat and Rev for HIV-1-Drug Profile 193

rAd5 Env A + rAd35 Env A Vaccine-Drug Profile 194

RC-100b-Drug Profile 195

Recombinant Enzyme for HIV-1 Infection-Drug Profile 196

Recombinant Peptide to Inhibit gp120 for HIV-1-Drug Profile 197

Recombinant Peptides for HIV-1 Infection and Influenza A Infections-Drug Profile 198

Recombinant Protein to Target gp120 for HIV-1 Infection-Drug Profile 199

Recombinant Protein to Target gp120 for HIV-1 Infections-Drug Profile 200

rilpivirine-Drug Profile 201

RN-18-Drug Profile 203

SB-105A10-Drug Profile 204

Small Molecule for HIV-1 Infection-Drug Profile 206

Small Molecule for HIV-1 Infection-Drug Profile 207

Small Molecule to Inhibit Gag for HIV-1 Infection-Drug Profile 208

Small Molecule to Inhibit HIV-1 Protease for HIV-1 Infection-Drug Profile 209

Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection-Drug Profile 210

Small Molecule to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection-Drug Profile 211

Small Molecule to Inhibit Reverse Transcriptase for HIV-1 infection-Drug Profile 212

Small Molecule to Target Capsid Protein for HIV-1 Infection-Drug Profile 213

Small Molecule to Target Matrix Protein for HIV-1 Infection-Drug Profile 214

Small Molecules for HIV-1 Infection-Drug Profile 215

Small Molecules for HIV-1 Infection-Drug Profile 216

Small Molecules for HIV-1 Infection-Drug Profile 217

Small Molecules for HIV-1 Infection-Drug Profile 218

Small Molecules for HIV-1 Infection-Drug Profile 219

Small Molecules for HIV-1 Infections-Drug Profile 220

Small Molecules for HIV-1, Neurodegenerative Disorders and Type 2 Diabetes-Drug Profile 221

Small Molecules for Retroviral Infections-Drug Profile 222

Small Molecules to Inhibit CDK9 for HIV-1 Infection-Drug Profile 223

Small Molecules to Inhibit Glycoprotein and HIV Integrase for HIV-1 Infection-Drug Profile 224

Small Molecules to Inhibit HIV-1 Integrase for HIV-1 Infection-Drug Profile 225

Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1-Drug Profile 227

Small Molecules to Inhibit HIV-1 Reverse Transcriptase for HIV-1 Infection-Drug Profile 228

Small Molecules to Inhibit HIV-1 RT for HIV-1 Infection-Drug Profile 229

Small Molecules to Inhibit Nef for HIV-1 Infections-Drug Profile 230

Small Molecules to Inhibit Nuclear Export for Viral Infections and Cancer-Drug Profile 231

Small Molecules to Inhibit p25 and gp120 for HIV-1 Infection-Drug Profile 232

Small Molecules to Inhibit Ribonuclease H for HIV-1 Infection-Drug Profile 233

Small Molecules to Target GP120 and Gp41 for HIV-1 Infections-Drug Profile 234

Stem Cell Therapy for HIV-1 Infection and Melanoma-Drug Profile 235

SV6-B-Drug Profile 236

SV6-C-Drug Profile 237

SVC-2-Drug Profile 238

SVH1-C-Drug Profile 239

SVH1-D-Drug Profile 240

Synthetic Peptide 2 for HIV-1 Infection-Drug Profile 241

Synthetic Peptide for HIV-1 Infection-Drug Profile 242

Synthetic Peptide for Oncology and Infectious Disease-Drug Profile 243

THV-01-Drug Profile 244

TMC-310911-Drug Profile 246

UB-421-Drug Profile 247

VAC-3S-Drug Profile 248

Vacc-4x-Drug Profile 250

Vacc-C5-Drug Profile 254

VIR-353-Drug Profile 256

VIR-576-Drug Profile 257

VRC-01-Drug Profile 258

VRC-02-Drug Profile 260

HIV-1 Infection-Recent Pipeline Updates 261

HIV-1 Infection-Dormant Projects 286

HIV-1 Infection-Discontinued Products 296

HIV-1 Infection-Product Development Milestones 298

Featured News & Press Releases 298

Appendix 308

Methodology 308

Coverage 308

Secondary Research 308

Primary Research 308

Expert Panel Validation 308

Contact Us 308

Disclaimer 309

List of Tables

Number of Products under Development for HIV-1 Infection, H1 2015 23

Number of Products under Development for HIV-1 Infection-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 26

Number of Products under Development by Companies, H1 2015 (Contd..1) 27

Number of Products under Development by Companies, H1 2015 (Contd..2) 28

Number of Products under Investigation by Universities/Institutes, H1 2015 30

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 31

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 32

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 33

Comparative Analysis by Late Stage Development, H1 2015 34

Comparative Analysis by Clinical Stage Development, H1 2015 35

Comparative Analysis by Early Stage Development, H1 2015 36

Comparative Analysis by Unknown Stage Development, H1 2015 37

Products under Development by Companies, H1 2015 38

Products under Development by Companies, H1 2015 (Contd..1) 39

Products under Development by Companies, H1 2015 (Contd..2) 40

Products under Development by Companies, H1 2015 (Contd..3) 41

Products under Development by Companies, H1 2015 (Contd..4) 42

Products under Investigation by Universities/Institutes, H1 2015 43

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 44

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 45

Products under Investigation by Universities/Institutes, H1 2015 (Contd..3) 46

Products under Investigation by Universities/Institutes, H1 2015 (Contd..4) 47

HIV-1 Infection-Pipeline by AlphaVax, Inc., H1 2015 48

HIV-1 Infection-Pipeline by AltraVax Inc., H1 2015 49

HIV-1 Infection-Pipeline by Aphios Corporation, H1 2015 50

HIV-1 Infection-Pipeline by Argos Therapeutics, Inc., H1 2015 51

HIV-1 Infection-Pipeline by Bionor Pharma ASA, H1 2015 52

HIV-1 Infection-Pipeline by Biosantech SA, H1 2015 53

HIV-1 Infection-Pipeline by Boehringer Ingelheim GmbH, H1 2015 54

HIV-1 Infection-Pipeline by Bristol-Myers Squibb Company, H1 2015 55

HIV-1 Infection-Pipeline by CompleGen, Inc., H1 2015 56

HIV-1 Infection-Pipeline by Critical Outcome Technologies Inc., H1 2015 57

HIV-1 Infection-Pipeline by CytoDyn Inc., H1 2015 58

HIV-1 Infection-Pipeline by Enzo Biochem, Inc., H1 2015 59

HIV-1 Infection-Pipeline by FIT Biotech Oy, H1 2015 60

HIV-1 Infection-Pipeline by GeneCure LLC, H1 2015 61

HIV-1 Infection-Pipeline by Gilead Sciences, Inc., H1 2015 62

HIV-1 Infection-Pipeline by GlaxoSmithKline plc, H1 2015 63

HIV-1 Infection-Pipeline by Heat Biologics, Inc., H1 2015 64

HIV-1 Infection-Pipeline by InnaVirVax SA, H1 2015 65

HIV-1 Infection-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 66

HIV-1 Infection-Pipeline by Johnson & Johnson, H1 2015 67

HIV-1 Infection-Pipeline by Merck & Co., Inc., H1 2015 68

HIV-1 Infection-Pipeline by Mymetics Corporation, H1 2015 69

HIV-1 Infection-Pipeline by Myrexis, Inc., H1 2015 70

HIV-1 Infection-Pipeline by Oncovir, Inc., H1 2015 71

HIV-1 Infection-Pipeline by OyaGen Inc., H1 2015 72

HIV-1 Infection-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 73

HIV-1 Infection-Pipeline by Pfizer Inc., H1 2015 74

HIV-1 Infection-Pipeline by Pharis Biotec GmbH, H1 2015 75

HIV-1 Infection-Pipeline by Spider Biotech, H1 2015 76

HIV-1 Infection-Pipeline by TaiMed Biologics Inc., H1 2015 77

HIV-1 Infection-Pipeline by Takara Bio Inc., H1 2015 78

HIV-1 Infection-Pipeline by Theravectys S.A., H1 2015 79

HIV-1 Infection-Pipeline by Tobira Therapeutics, Inc., H1 2015 80

HIV-1 Infection-Pipeline by United Biomedical, Inc., H1 2015 81

HIV-1 Infection-Pipeline by Valens Therapeutics, Inc., H1 2015 82

HIV-1 Infection-Pipeline by Vichem Chemie Research Ltd., H1 2015 83

HIV-1 Infection-Pipeline by ViiV Healthcare Limited, H1 2015 84

Assessment by Monotherapy Products, H1 2015 85

Assessment by Combination Products, H1 2015 86

Number of Products by Stage and Target, H1 2015 88

Number of Products by Stage and Mechanism of Action, H1 2015 91

Number of Products by Stage and Route of Administration, H1 2015 94

Number of Products by Stage and Molecule Type, H1 2015 96

HIV-1 Infection Therapeutics-Recent Pipeline Updates, H1 2015 271

HIV-1 Infection-Dormant Projects, H1 2015 296

HIV-1 Infection-Dormant Projects (Contd..1), H1 2015 297

HIV-1 Infection-Dormant Projects (Contd..2), H1 2015 298

HIV-1 Infection-Dormant Projects (Contd..3), H1 2015 299

HIV-1 Infection-Dormant Projects (Contd..4), H1 2015 300

HIV-1 Infection-Dormant Projects (Contd..5), H1 2015 301

HIV-1 Infection-Dormant Projects (Contd..6), H1 2015 302

HIV-1 Infection-Dormant Projects (Contd..7), H1 2015 303

HIV-1 Infection-Dormant Projects (Contd..8), H1 2015 304

HIV-1 Infection-Dormant Projects (Contd..9), H1 2015 305

HIV-1 Infection-Discontinued Products, H1 2015 306

HIV-1 Infection-Discontinued Products (Contd..1), H1 2015 307

List of Figures

Number of Products under Development for HIV-1 Infection, H1 2015 23

Number of Products under Development for HIV-1 Infection-Comparative Analysis, H1 2015 24

Number of Products under Development by Companies, H1 2015 25

Number of Products under Investigation by Universities/Institutes, H1 2015 29

Comparative Analysis by Late Stage Development, H1 2015 34

Comparative Analysis by Clinical Stage Development, H1 2015 35

Comparative Analysis by Early Stage Products, H1 2015 36

Assessment by Monotherapy Products, H1 2015 85

Assessment by Combination Products, H1 2015 86

Number of Products by Top 10 Targets, H1 2015 87

Number of Products by Stage and Top 10 Targets, H1 2015 87

Number of Products by Top 10 Mechanism of Actions, H1 2015 90

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 90

Number of Products by Top 10 Routes of Administration, H1 2015 93

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 93

Number of Products by Top 10 Molecule Types, H1 2015 95

Number of Products by Stage and Top 10 Molecule Types, H1 2015 95

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

AlphaVax, Inc.

AltraVax Inc.

Aphios Corporation

Argos Therapeutics, Inc.

Bionor Pharma ASA

Biosantech SA

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

CompleGen, Inc.

Critical Outcome Technologies Inc.

CytoDyn Inc.

Enzo Biochem, Inc.

FIT Biotech Oy

GeneCure LLC

Gilead Sciences, Inc.

GlaxoSmithKline plc

Heat Biologics, Inc.

InnaVirVax SA

Inovio Pharmaceuticals, Inc.

Johnson & Johnson

Merck & Co., Inc.

Mymetics Corporation

Myrexis, Inc.

Oncovir, Inc.

OyaGen Inc.

Peregrine Pharmaceuticals, Inc.

Pfizer Inc.

Pharis Biotec GmbH

Spider Biotech

TaiMed Biologics Inc.

Takara Bio Inc.

Theravectys S.A.

Tobira Therapeutics, Inc.

United Biomedical, Inc.

Valens Therapeutics, Inc.

Vichem Chemie Research Ltd.

ViiV Healthcare Limited

HIV-1 Infection Therapeutic Products under Development, Key Players in HIV-1 Infection Therapeutics, HIV-1 Infection Pipeline Overview, HIV-1 Infection Pipeline, HIV-1 Infection Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com